Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board

Full article from Infinity Pharmaceuticals

CAMBRIDGE, Mass., March 8, 2018 /PRNewswire/ — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it has added to its Board of Directors, expanded its clinical leadership team, and established a Scientific Advisory Board.

“We are pleased to announce the appointment of David Beier, J.D. to our Board of Directors,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “David’s deep insights on healthcare policy, economics and drug pricing, together with his perspectives as an advisor to the Parker Institute for Cancer Immunotherapy, will be invaluable as we advance IPI-549, a potentially first-in-class immuno-oncology medicine.”

“We are also thrilled to have Dr. Marie-Louise Fjällskog, join the exceptional clinical team at Infinity and to recognize the contributions of Dr. Suresh Mahabhashyam, in the development of IPI-549,” Ms. Perkins continued. “In addition, we are delighted to announce the establishment of a Scientific Advisory Board with key immuno-oncology thought leaders, including Dmitry Gabrilovich, M.D., Ph.D., Roy Herbst, M.D., Ph.D., Stephen Hodi, M.D., and David Munn, M.D. The depth of their collective clinical oncology experience, especially in the rapidly-evolving field of immuno-oncology, will be critical as we generate important data on IPI-549 this year and determine the optimal path forward for this first-in-class product candidate.”

David Beier, J.D., is a Managing Director of Bay City Capital and brings a wealth of experience to the Infinity Board. David serves as an advisor to the Parker Institute for Cancer Immunotherapy, a Senior Fellow at the USC Schaeffer Center for Health Policy & Economics and as a member of the Board of Directors of Arcus Biosciences, UCSF Benioff Children’s Hospitals and the California Life Sciences Association. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. Having spent two decades as part of the senior management teams for Amgen and Genentech, he brings invaluable perspective regarding strategy for entrepreneurial biotechnology firms and the industry in general as a globally recognized leader in health care policy, regulatory affairs, healthcare economics, and pricing. Mr. Beier also previously served in the White House during the Clinton Administration as a Chief Domestic Policy Advisor to the Vice President.

“Infinity has a tremendous team, including top-tier investigators, advisors, board, and management,” said Mr. Beier. “I look forward to working with them to optimize the value of IPI-549 for patients and shareholders, based on important data being generated on IPI-549 this year.”


< Back to News & Events